Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Inventory (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Change in Inventory for 3 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 78.86% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.2 million, a 67.98% decrease, with the full-year FY2025 number at $14.2 million, down 67.98% from a year prior.
  • Change in Inventory was $4.0 million for Q4 2025 at Iovance Biotherapeutics, up from $3.2 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $18.9 million in Q4 2024 to a low of -$6.9 million in Q2 2025.
  • A 3-year average of $6.2 million and a median of $6.7 million in 2024 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: soared 2885.59% in 2024, then tumbled 178.36% in 2025.
  • Iovance Biotherapeutics' Change in Inventory stood at $923000.0 in 2023, then surged by 1950.6% to $18.9 million in 2024, then crashed by 78.86% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Change in Inventory are $4.0 million (Q4 2025), $3.2 million (Q3 2025), and -$6.9 million (Q2 2025).